<DOC>
	<DOCNO>NCT01588314</DOCNO>
	<brief_summary>The purpose study determine efficacy gabapentin vs. placebo control peripheral neuropathic pain patient Fabry disease , reduce use opioid analgesic . The investigator conduct randomized , double-blind , placebo control , single center , cross-over study . The primary endpoint percent reduction patient ' use hydrocodone-acetaminophen .</brief_summary>
	<brief_title>Safety Efficacy Gabapentin Neuropathic Pain Fabry Disease</brief_title>
	<detailed_description>Fabry disease X-linked lysosomal storage disorder result reduce activity enzyme α-galactosidase A . This reduced enzyme activity result accumulation globotriaosylceramide ( GL-3 ) , cause disturbance multiple organ system . Patients often complain acroparesthesia , cause small-fiber neuropathy . Limited information available regard effective treatment small-fiber neuropathic pain Fabry disease , standard-of-care yet establish . Opioid analgesic often use pharmacokinetic property . While effective , use opioids complication constipation , physical dependence addiction . The purpose study determine efficacy gabapentin vs. placebo control peripheral neuropathic pain reduce use opioid analgesic . The investigator conduct randomized , double-blind , placebo control , single center , cross-over study . The primary endpoint percent reduction hydrocodone-acetaminophen use .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>diagnosis Fabry Disease age ≥ 18 year age study enrollment current neuropathic pain severity level know sensitivity allergy study drug history illicit drug use pregnancy suicidal thought study enrollment ass CSSRS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>gabapentin</keyword>
</DOC>